Key Takeaways
- AbbVie maintains an average brokerage recommendation of 1.61 (between Strong Buy and Buy) from 32 Wall Street firms, including 21 Strong Buy ratings
- Citi and UBS both increased their ABBV price targets to $260 from previous $230 levels
- Both financial institutions continue to hold Neutral ratings despite the price target increases
- Zacks currently assigns ABBV a Rank #4 (Sell), noting the consensus EPS forecast for this year declined 0.6% to $14.23
- According to GuruFocus analysis, ABBV appears approximately 16.4% overvalued, trading at a P/E ratio of 121.77x compared to its 5-year median of 47.36x
AbbVie (ABBV) has captured Wall Street’s focus this week as two prominent investment banks increased their price objectives ā though their recommendations remain tepid.
With ABBV shares hovering near $247.19 based on recent market data, both Citi and UBS established fresh $260 targets, representing an increase from their prior $230 projections. This marks a 13% upward revision in anticipated value. However, both institutions maintained their Neutral stance, suggesting they’re not enthusiastically endorsing the stock.
Citi’s Geoff Meacham implemented this adjustment while conducting a comprehensive Q2 earnings analysis for the biopharmaceutical sector. The firm anticipates “largely robust” second-quarter performance from major-cap stocks under its coverage. UBS analyst Michael Yee mirrored this measured approach ā elevating the target while preserving a neutral position.
The conflicting indicators continue beyond these updates.
AbbVie’s average brokerage recommendation (ABR) from 32 financial institutions stands at 1.61 ā positioned between Strong Buy and Buy categories.
Among these 32 assessments, 21 are classified as Strong Buy and two as Buy. On the surface, this appears decidedly bullish.
Yet Zacks presents an alternative perspective.
Zacks Issues Sell Recommendation for ABBV
AbbVie currently holds a Zacks Rank of #4 (Sell). The Zacks Consensus Estimate for annual EPS has declined 0.6% during the last 30 days, now positioned at $14.23. Analysts have been gradually reducing their earnings projections, a pattern that Zacks considers significantly in its methodology.
Zacks emphasizes that brokerage recommendations ā despite their widespread influence ā frequently exhibit positive bias stemming from business relationships firms maintain with covered companies. Their research indicates analysts distribute approximately five Strong Buy ratings for each Strong Sell recommendation. Therefore, that ABR of 1.61 may not represent the straightforward endorsement it initially appears.
The valuation assessment introduces additional complexity. GuruFocus calculates AbbVie’s GF Value at $212.31, positioning the current share price roughly 16.4% beyond their fair value determination. The stock’s trailing P/E ratio stands at 121.77x ā exceeding its five-year median of 47.36x by more than double.
GF Score Analysis and Management Trading
GuruFocus assigns ABBV a GF Score of 81 out of 100, indicating strong overall metrics. Profitability receives an 8/10 rating while growth scores 7/10. Financial strength, however, registers only 4/10 ā a metric deserving attention.
Regarding insider transactions, there has been zero buying or selling activity documented during the previous three months. Company insiders remain inactive.
AbbVie is scheduled to announce Q2 earnings imminently, and Citi’s preliminary assessment suggests the results may prove substantial. The stock has gained approximately 1% during the current trading session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
